Eveliqure and Serum Institute of India Partner to Develop Anti-Diarrhoeal Vaccines
Eveliqure and Serum Institute of India (SII) have partnered to develop anti-diarrhoeal vaccines, with Eveliqure set to receive an upfront payment, milestone-based earnings and royalties on net sales, while SII will lead development and global commercialisation.
ShigETEC | 23/03/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy